{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2017)
Source URL:
First approved in 2017
Source:
21 CFR 333D
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 331
(2019)
Source URL:
First approved in 2017
Source:
M032
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Cellzyme Secret Therapy by PHARMACAL-INTERNATIONAL. CO., LTD
(2017)
Source URL:
First approved in 2017
Source:
Cellzyme Secret Therapy by PHARMACAL-INTERNATIONAL. CO., LTD
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BOTANIC TWENTY HYPERCARE PLUMPING FORMULA by RITZY NOBLE CO., LTD.
(2018)
Source URL:
First approved in 2017
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2017)
Source URL:
First approved in 2017
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2017
Source:
LumaSilk Emulsion Level 02 by The Skin Atelier, Inc.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M020
(2022)
Source URL:
First approved in 2017
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M013
(2024)
Source URL:
First approved in 2017
Source:
21 CFR 347
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2017)
Source URL:
First approved in 2017
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT04487613: Phase 4 Interventional Completed Postpartum Women
(2021)
Source URL:
First approved in 2017
Source:
MIRACLE SOS GOLD by Ddoruroo Co., Ltd.
Source URL:
Class:
STRUCTURALLY DIVERSE